| Editor's Note: The Fierce PM Tracker will be taking a publishing break for the winter holidays. We’ll be back in your inboxes January 3, 2023. |
Today's Big NewsDec 22, 2022 |
|
Jan 11, 2023 | 2:00pm ET Recent advances in natural language processing (NLP) caused an explosion of practical use cases that have now become viable. This webinar for healthcare & life sciences leaders surveys common NLP applications that are being widely deployed, including real world data extraction from pathology & radiology reports, patient risk adjustment & HCC coding, and more. Register now. 
|
|
| By Annalee Armstrong A third patient death potentially tied to Eisai and Biogen’s Alzheimer’s disease drug lecanemab has been reported in a phase 3 extension study, according to a report from Science. |
|
|
|
By Dave Muoio While exceptions remain, the Society for Healthcare Epidemiology of America said blanket asymptomatic screening has "unclear benefit" when layered upon a healthcare facility’s other infection prevention measures. |
By Zoey Becker It's no question that Gilead is on top of the HIV game, but throughout the HIV epidemic, one patient population has been left out. The FDA approved Gilead's lenacapivir, a long-acting HIV injectable, for patients whose virus is resistant to multiple drugs. |
By Andrea Park Six months after leaving the BD nest, Embecta seems to be well on its way to carving out its own path within the medtech industry. |
|
Tuesday, January 24, 2023 | 11am ET / 8am PT UGTs are the most common enzymes involved in metabolism after CYP enzymes, followed by numerous hydrolases, carbonyl reductases, aldehyde oxidase and other enzymes. Hear Dr. Brian Ogilvie discuss case studies and strategies to address non-CYP related metabolism questions in your drug’s safety assessment. Register now. 
|
|
By Annalee Armstrong In one of the most lopsided biobucks deals this publication has ever seen, Merck & Co. is offering $175 million upfront to Kelun-Biotech for seven antibody-drug conjugates, plus an eye-popping $9.3 billion in potential milestones on the tail end. |
By Zoey Becker Pfizer and Sanofi reached an out-of-court settlement with the plaintiff in a California case that was slated for trial, Bloomberg reports. |
By Conor Hale Sysmex received approval within the country for a two-step test kit that gauges the ratio between two beta amyloid proteins in the bloodstream. |
By Max Bayer A leak of the Whitehead Institute's investigation into David Sabatini has come to light, detailing claims against the former MIT professor. The report concluded that Sabatini fostered a toxic culture in his lab and interfered in the institute's investigation. |
By Kevin Dunleavy Moderna’s planned manufacturing site in the United Kingdom will have the ability to churn out 250 million vaccine doses annually, the company said on Thursday. As for the exact location of the facility? Stay tuned. |
By Dave Muoio With no shortage of hurdles in store for 2023, hospital finance experts offered seven quick wins and big-picture goals they believe executive teams should have in mind going into the new year. |
By Frank Diamond Provisions of the Consolidated Appropriations Act that go into effect next year will give employers who self-insure more oversight of the health benefits they provide for their employees. |
By Annalee Armstrong,Max Bayer,Gabrielle Masson After a brutal year in the markets that saw companies slashing programs, culling staff and reorganizing, the industry is much leaner and preparing to find its voice again. |
By Conor Hale For 2020 and 2021, our year-end lists of the most-read articles were dominated by COVID-19—and rightly so, with the coronavirus being front-of-mind as it grew to define our daily lives. But this year? Not so much. |
Fierce podcasts Don't miss an episode |
| This week on "Podnosis," we talk about this year's class of digital health companies that crossed the $1 billion valuation despite an overall funding slowdown. We also discuss how best to leverage population health management to improve how care is delivered and make it more holistic. |
|
|---|
|
|
|
Tuesday, January 24, 2023 | 11am ET / 8am PT Your CRO is a finalist in a project bid and clinical supplies are one of the aspects that you will manage on behalf of the client via a partner. Register now. 
|
|
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Executive Summary Strategies to help scale-up for commercial manufacturing are critical to getting cell and gene therapies to patients as more advanced therapies reach late-stage clinical studies and regulatory decisions. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| |
|
